Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Review ArticleReview

Anakinra for Rheumatoid Arthritis: A Systematic Review

MARTY MERTENS and JASVINDER A. SINGH
The Journal of Rheumatology June 2009, 36 (6) 1118-1125; DOI: https://doi.org/10.3899/jrheum.090074
MARTY MERTENS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JASVINDER A. SINGH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Jasvinder.md@gmail.com
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Collection of studies for the systematic review.

Tables

  • Figures
    • View popup
    Table 1.

    Studies included in this systematic review.

    StudyNo. of ParticipantsDurationInterventionsOutcomesMethodological Quality*Notes
    Bresnihan 19983347224 wksPlacebo (n = 119), 30 mg anakinra (n = 119), 75 mg anakinra (n = 115), 150 mg anakinra (n = 115)ACR 20, HAQ, VAS (pain), ESR, CRP, Larsen scores, withdrawals, injection site reactionsSilver; no intention-to-treat analysis; method of randomization was not reported; 26.7% withdrawal rateExcluded patient data from analysis if outcome data was missing
    Cohen 20023531724 wksPlacebo (n = 48), 0.04 mg/kg (n = 63), 0.1 mg/kg (n = 46), 0.4 mg/kg (n = 55), 1.0 mg/kg (n = 59), 2.0 mg/kg (n = 46) daily. Methotrexate was required for inclusion in this studyACR20/50/70, withdrawals, injection site reactions (continuous data not included as no SD/SE data provided)Silver; method of randomization was not reported; blinding was only described for the patients; 21% withdrawal rate at 24 weeksOriginally designed as a 12 wk trial, expanded to 24 wks; only 3 patients reconsented to the 24 wk study
    Cohen 20043650624 wksPlacebo (n = 251), anakinra 100 mg daily (n = 250)ACR20/50/70, HAQ, ESR, injection site reactions, adverse events (total, serious), infections (total, serious),Silver; no intention-to-treat analysis; method of randomization was not reportedNumber of total withdrawals was not reported in this study
    Fleischman 20033414146 moPlacebo (n = 283), anakinra 100 mg daily (n = 1116)withdrawals, injection site reactions, deaths, adverse events (total, serious), infections (total, serious)Silver; no intention-to-treat analysis; method of randomization was not reported; 21.9% withdrawal rate
    Genovese 20043724424 wksPlacebo + etanercept 25 mg biweekly (n = 80) anakinra 100 mg daily + etanercept 25 mg weekly (n = 81), anakinra 100 mg daily + etanercept 25 mg biweekly (n = 81). Methotrexate was required for inclusion in this studyACR20/50/70, withdrawals, injection site reactions, adverse events (total, serious), infections (total, serious)Silver; though full blinding was only reported for the patients; no intention-to-treat analysis; method of randomization was not reported; 17.4% withdrawal rateThe anakinra+ etanercept 25 mg weekly group did not have a placebo-controlled comparison
    • ↵* Methodological quality was defined using the system described by Tugwell, et al30 as follows: Platinum: A published systematic review that has at least 2 individual controlled trials each satisfying the following: Sample size of at least 50 per group — if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome. Blinding of patients and assessors for outcomes. Handling of withdrawals > 80% followup [imputations based on methods such as last observation carried forward (LOCF) are acceptable]. Concealment of treatment allocation. Gold: At least 1 randomized clinical trial meeting all the following criteria for the major outcome(s) as reported: Sample sizes of at least 50 per group — if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome. Blinding of patients and assessors for outcomes. Handling of withdrawls > 80% followup (imputations based on methods such as LOCF are acceptable). Concealment of treatment allocation. Silver: A randomized trial that does not meet the above criteria. Silver ranking would also include evidence from at least 1 study of non-randomized cohorts that did and did not receive the therapy, or evidence from at least one high quality case-control study. A randomized trial with a “head-to-head” comparison of agents would be considered silver level ranking unless a reference were provided to a comparison of one of the agents to placebo showing at least a 20% relative difference. Bronze: The bronze ranking is given to evidence if a least 1 high quality case series without controls (including simple before/after studies in which patients act as their own control) or if the conclusion is derived from expert opinion based on clinical experience without reference to any of the foregoing (for example, argument from physiology, bench research, or first principles). ACR: American College of Rheumatology; HAQ: Health Assessment Questionnaire; VAS: visual analog scale; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SD/SE: standard deviation/error.

    • View popup
    Table 2.

    Anakinra (50–150 mg/kg) vs placebo, ACR 20/50/70 at 24 wks.

    ACR20ACR50ACR70
    Study (Reference)Anakinra n/N (%)Placebo n/N (%)NNTAnakinra n/N (%)Placebo n/N (%)NNTAnakinra n/N (%)Placebo n/N (%)NNT
    Anakinra vs placebo
    Bresnihan 19983388/230 (38)32/119 (27)9.1No dataNo dataNo dataNo dataNo dataNo data
    Fleischman 200334No dataNo dataNo dataNo dataNo dataNo dataNo dataNo dataNo data
    Anakinra + Methotrexate vs Placebo + Methotrexate
    Cohen 20023541/105 (39)11/48 (23)6.322/105 (21)2/48 (4)5.99/105 (9)0/48 (0)11.1
    Cohen 20043695/250 (38)55/251 (22)6.343/250 (17)20/251 (8)11.115/250 (6)5/251 (2)25
    Totals (w/o Genovese)224/585 (38)98/418 (23)6.765/355 (18)22/299 (7)9.124/355 (7)5/299 (2)20
    Anakinra + Methotrexate + Etanercept vs Placebo + Methotrexate + Etanercept
    Genovese 20043750/81 (62)54/80 (68)NA25/81 (31)33/80 (41)NA11/81 (14)17/80 (21)NA
    Totals (w/Genovese)274/666 (41)152/498 (31)1090/436 (21)55/379 (15)16.735/436 (8)22/379 (6)50
    • NA: not available.

    • View popup
    Table 3.

    Secondary outcome data for anakinra 50–150 mg compared to placebo†.

    Mean at BaselineMean Difference (Confidence intervals)Relative Change from Baseline*Studies Providing Data
    Change in HAQ1.49−0.19 (−0.30, −0.09)0.13Bresnihan 199833
    Cohen 200436
    Change in VAS (pain)0.64−0.10 (−0.15, −0.04)0.16Bresnihan 199833
    Change in Larsen scores13.5−2.45 (−4.53, −0.36)0.18Bresnihan 199833
    Change in ESR45.97−10.04 (−12.75, −7.33)0.22Bresnihan 199833
    Cohen 200436
    Change in CRP4.1−0.6 (−1.26, 0.06)0.15Bresnihan 199833
    • ↵† Data exclude outcome data from Genovese 200437.

    • ↵* Relative change from baseline = mean difference/mean at baseline. HAQ: Health Assessment Questionnaire; VAS: visual analog scale; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.

    • View popup
    Table 4.

    Safety outcome data for anakinra 50–150 mg compared to placebo†.

    Anakinra, n/N (%)Placebo, n/N (%)Absolute Risk Difference (%)NNH*Risk Ratio (Confidence intervals)Studies
    Withdrawals331/1479 (22.4)106/478 (22.2)0.25001.04 (0.86, 1.27)Cohen 200235
    Fleischman 200334
    Bresnihan 199833
    Deaths4/1116 (0.4)1/283 (0.4)0α1.01 (0.11, 9.04)Fleischman 200334
    Adverse events1252/1366 (91.7)464/534 (86.9)4.820.81.05 (0.94, 1.17)Fleischman 200334
    Cohen 200436
    Serious adverse events96/1366 (7.0)30/534 (5.6)1.4711.04 (0.70, 1.56)Fleischman 200334
    Cohen 200436
    Injection site reactions1235/1729 (71.4)204/729 (28.0)43.42.32.45 (2.17, 2.77)Cohen 200235
    Cohen 200436
    Fleischman 200334
    Bresnihan 199833
    Total infections543/1366 (39.8)188/534 (35.2)4.5221.08 (0.80, 1.45)Fleischman 200334
    Cohen 200436
    Serious infections25/1366 (1.8)3/534 (0.6)1.2833.15 (0.81, 12.20)Fleischman 200334
    Cohen 200436
    • ↵† Data exclude safety data from Genovese 200437.

    • ↵* NNH (number needed to harm) = 1/absolute risk difference.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 6
1 Jun 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anakinra for Rheumatoid Arthritis: A Systematic Review
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anakinra for Rheumatoid Arthritis: A Systematic Review
MARTY MERTENS, JASVINDER A. SINGH
The Journal of Rheumatology Jun 2009, 36 (6) 1118-1125; DOI: 10.3899/jrheum.090074

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Anakinra for Rheumatoid Arthritis: A Systematic Review
MARTY MERTENS, JASVINDER A. SINGH
The Journal of Rheumatology Jun 2009, 36 (6) 1118-1125; DOI: 10.3899/jrheum.090074
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Overview of Imaging in Adult- and Childhood-onset Takayasu Arteritis
  • The ASAS Health Index: A New Era for Health Impact Assessment in Spondyloarthritis
  • Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs
Show more Review

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire